INM

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov. "This has been an important year for InMed as we position InMed for its next phase through the proposed merger with Mentari Therapeutics, Inc.," commented Eric A. Adams, InMed President and CEO. "The additional $200 million private placement announced by Mentari brings the expected aggregate pre-closing financing to approximately $490 million and further strengthens the combined company as we work toward completing the transaction by the end of the calendar year 2026. In parallel, we remain focused on maximizing the potential value of our legacy pharmaceutical programs for InMed shareholders through a Contingent Value Rights ("CVR") structure, including pursuing strategic opportunities for INM-901, INM-089 and INM-755." Corporate Update Proposed Merger with Mentari Therapeutics In May 2026, InMed entered into a definitive merger agreement with Mentari Therapeutics, Inc. ("Mentari"), a privately held biotechnology company developing next-generation therapies for migraine prevention. Upon closing of the proposed merger (the "Merger"), the combined company is expected to operate as Mentari Therapeutics, Inc. and trade on the Nasdaq Capital Market under the ticker symbol "MTRI". The combined company will focus on advancing Mentari's pipeline of migraine prevention therapies. In May 2026, in connection with the Merger, Mentari announced an oversubscribed $290 million private placement. In July 2026, Mentari announced an additional $200 million private placement from existing and new investors, increasing the expected aggregate gross proceeds from the pre-closing financing to approximately $490 million. The expanded financing is expected to extend the combined company's cash runway into 2029 and through Phase 2a readouts for each of Mentari's two PACAP-targeted lead programs, as well as support the clinical development of Mentari's broader migraine prevention pipeline. In July 2026, InMed filed a registration statement on Form S-4 (the "Form S-4") with the U.S. Securities and Exchange Commission in connection with the Merger that includes a preliminary proxy statement/prospectus of InMed and a management information circular and subsequently announced an amendment to the merger agreement that, among other matters, clarified the sequencing of certain transactions, the impact of the pre-closing financing on the exchange ratio and the intended tax treatment of the Merger. The Form S-4 has not yet become effective. After the Form S-4 is declared effective, InMed will mail a definitive proxy statement/prospectus and management information circular to its shareholders and to Mentari's stockholders. The Merger remains on track to close in the fourth quarter of calendar year 2026, subject to the satisfaction or waiver of customary closing conditions, including approval by InMed shareholders and Mentari stockholders and the effectiveness of the Form S-4. InMed Pharmaceutical Assets InMed continues to pursue strategic opportunities for its legacy pharmaceutical development programs, including INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration and INM-755 for dermatology. Under the terms of the proposed transaction, legacy InMed shareholders are expected to receive CVRs related to the potential future monetization of these programs. During the fiscal year, InMed continued to advance the development and transaction readiness of INM-901. The Company recently conducted a pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration ("FDA") for the INM-901 program and is integrating FDA feedback into drug development planning. InMed also continues to engage with potential strategic parties regarding opportunities to acquire or license INM-901, INM-089 and/or INM-755. Discontinued Operations During the fiscal year, a decision was made to discontinue the operations of InMed's wholly owned subsidiary, BayMedica, LLC ("BayMedica"). As of June 30, 2026, BayMedica had wound down all of its operating activities, as well as terminated its commercial lease at the end of August 2026. BayMedica's financial results are presented as discontinued operations in the Company's consolidated financial statements. Financial Commentary For the fiscal year ended June 30, 2026, the Company recorded a net loss of$12.9 million, compared with a net loss of $8.2 million for the previous fiscal year. Research and development expenses were $3.0 million for the fiscal year ended June 30, 2026, compared with $2.8 million for the fiscal year ended June 30, 2025. The increase in research and development expenses was primarily due to an increase in external contractors and personnel costs. General and administrative expenses were $6.7 million for the fiscal year ended June 30, 2026, compared with $5.4 million for the fiscal year ended June 30, 2025. The increase was primarily due to increased corporate legal expenses and personnel costs, partially offset by a decrease in patent related expenses and investor relations expenses. For the fiscal year ended June 30, 2026, BayMedica, which is presented as discontinued operations, recorded sales of $3.2 million compared with $5.0 million for the fiscal year ended June 30, 2025. As of June 30, 2026, the Company had cash, cash equivalents and short-term investments of $2.2 million. Table 1. Consolidated Balance Sheet(Expressed in US Dollars) Table 2. Consolidated Statement of Operations(Expressed in US Dollars) Table 3. Consolidated Statements of CashflowsExpressed in US Dollars About InMed InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin ClancyVice President, Investor Relationsand Corporate CommunicationsT: +1.604.416.0999E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements regarding the proposed merger with Mentari, including the anticipated timing and completion of the merger and other contemplated transactions; the expected aggregate proceeds from the pre-closing financing; the expected cash runway of the combined company; the potential future monetization of INM-901,INM-089 and INM-755; the Company's efforts to identify strategic opportunities for INM-901, INM-089 and INM-755; the expected nature, focus and operations of the combined company following the merger; and the integration of comments from a pre-IND meeting with the FDA for INM-901. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; the satisfaction or waiver of the conditions to the completion of the proposed merger with Mentari, including the receipt of required shareholder and stockholder approvals; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, as may be updated from time to time by InMed's Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission available at www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. No Offer or Solicitation This communication is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, or the solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Without limiting the foregoing, this communication does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in connection with any private placement or other financing by Mentari or InMed. Any such securities have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an applicable exemption therefrom. Important Additional Information About the Merger and Where to Find It In connection with the proposed merger, InMed has filed with the SEC a registration statement on Form S-4 that includes a preliminary proxy statement/prospectus of InMed and a management information circular and will file other relevant documents with the SEC and applicable Canadian securities regulators. The Form S-4 has not yet become effective. After the Form S-4 is declared effective, InMed will mail a definitive proxy statement/prospectus and management information circular to its shareholders and to Mentari's stockholders. INVESTORS AND SECURITYHOLDERS OF INMED AND MENTARI ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT/PROSPECTUS AND MANAGEMENT INFORMATION CIRCULAR (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS) AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT INMED, MENTARI, THE MERGER AND RELATED MATTERS. Investors and securityholders may obtain free copies of these documents (when available) through the SEC's website at www.sec.gov, on SEDAR+ at www.sedarplus.ca, or from InMed at inmedpharma.com/investors. Participants in the Solicitation InMed, Mentari and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from InMed's shareholders and Mentari's stockholders in connection with the proposed merger. Information regarding InMed's directors and executive officers and a description of their direct and indirect interests, by security holdings or otherwise, is set forth in InMed's most recent annual report on Form 10-K and its other filings with the SEC and on SEDAR+. Additional information regarding the participants and their interests is or will be contained in the proxy statement/prospectus and management information circular and other relevant materials filed or to be filed with the SEC and Canadian securities regulators. These documents may be obtained free of charge as described above. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313685

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026. The Company's full financial statements and related MD&A for the third quarter ended March 31, 2026, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov. "During the quarter, InMed reported additional preclinical data that further support the development of INM-901 for Alzheimer's disease through its targeting of neuroinflammation. Data from advanced human brain organoid systems demonstrated anti-neuroinflammatory effects consistent with findings observed across multiple in vivo and ex vivo studies," commented Eric A. Adams, InMed President and CEO. Business Update INM-901: Targeting the Modulation of Neuroinflammation in Alzheimer's disease InMed's proprietary, disease-modifying, small molecule drug candidate INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and continues to advance as a potential treatment for Alzheimer's disease with a primary focus on modulating neuroinflammation. During the quarter, InMed announced preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. The in vitro human organoid models represent some of the closest approximations to human brain tissue currently available, incorporating a complex cellular environment relevant to neurodegenerative disease. The organoids are composed of neurons, astrocytes, vascular cells and feature microglia, the brain's resident immune cells, and can be used to bridge the gap between traditional animal models and human clinical trials. INM-901 was evaluated in two distinct human 3D organoid models: a general model of neuroinflammation induced with lipopolysaccharide ("LPS") and interferon-gamma ("IFN-γ"); and, Stem Pharm's proprietary neuroinflammation Alzheimer's disease model with specific features observed in Alzheimer's disease patients. Key Observations included: INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models. Effects align with prior findings from an in vivo Alzheimer's model and an ex vivo LPS-induced neuroinflammation model. Provides supportive evidence of mechanistic translation from animal models to human tissue systems. The consistency of INM-901's anti-inflammatory effects across in vivo animal models, ex vivo systems and now human 3D brain organoids provide increasing confidence in the compound's potential to translate into clinical benefit in humans with neuroinflammatory conditions. Discontinued Operations On March 4, 2026, the Company's board of directors ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica's commercial operations business segment ("Commercial Operations"), which is the only revenue-generating commercial operations of the Company. BayMedica intends to substantially complete the wind down and exit prior to the end of its fiscal year ending June 30, 2026. During the interim period leading to the completion of operational wind down, BayMedica will continue its commercial operations including sales, marketing, limited manufacturing, and logistics. Financial Commentary Following the classification of the Commercial segment as discontinued operations, the Company has one reportable segment that constitutes consolidated results consisting of its operations. Unless otherwise noted, all activities and amounts reported in the following notes relate to the continuing operations of the Company and exclude activities and amounts related to discontinued operations. For the three months ended March 31, 2026, the Company reported a net loss of $3.0 million, compared to a net loss of $2.1 million in the same period the previous year. The increase was largely driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs. Pharmaceutical research and development for continuing operations were $1.0 million for the three months ended March 31, 2026, compared with $0.4 million for the three months ended March 31, 2025. The increase was primarily due to an increase in external contractors relating to our INM-901 program General and administrative expenses for continuing operations were $1.7 million for the three months ended March 31, 2026, compared to $1.6 million the same period the previous year. The increase resulted primarily from a combination of changes including lower accounting fees, share-based payments fees, and shareholder communication fees. As of March 31, 2026, the Company's cash, cash equivalents and short-term investments were $5.2 million, which compares to $10.8 million on June 30, 2025. The Company reported no revenue from continuing operations for the period. The discontinued commercial operations generated revenue of $0.7 million during the period; however, its results are classified as discontinued operations and are presented separately from continuing operations. Table 1. Consolidated Balance Sheet Expressed in U.S. Dollars Table 2. Consolidated Statements of Operations Expressed in U.S. Dollars Table 3. Consolidated Statements of Cash Flows Expressed in U.S. Dollars About InMed InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296317

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025. The Company's full financial statements and related MD&A for the second quarter ended December 31, 2025 are available at www.inmedpharma.com, www.sedarplus.ca and at www.sec.gov. Eric A. Adams, InMed Chief Executive Officer, commented, "We are pleased with the steady progress across our pharmaceutical pipeline as we look ahead to pursuing pre-IND meetings with the FDA in 2026. In our INM-901 program, compelling data from the preclinical studies demonstrated a significant reduction in key neuroinflammatory markers, reinforcing neuroinflammation as the central focus of our drug development activities." Business Update - Pharmaceutical Development Programs INM-901: Targeting the Modulation of Neuroinflammation in Alzheimer's disease InMed's proprietary, disease-modifying, small molecule drug candidate INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and continues to advance as a potential treatment for Alzheimer's disease with a primary focus on modulating neuroinflammation. During the quarter, InMed announced the successful completion of pharmacokinetic studies in clinically relevant in vivo models for INM-901. This marked the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program. Over a seven-day dosing period, the studies demonstrated robust bioavailability, achieving what is anticipated to be therapeutic levels of systemic exposure for INM-901. In addition, neurological assessments evaluating general attitude, behavior, and motor function revealed no adverse neural or behavioral effects, reinforcing the compound's favorable profile and supporting its continued advancement toward first-in-human clinical trials. Next development steps: Advancing CMC activities for scale-up and supply Dose ranging studies in two species Preparing for a pre-IND meeting with the FDA GLP-enabling studies to support an IND submission INM-089: Neuroprotection in the treatment of dry age-related macular degeneration ("AMD") INM-089 is a proprietary, disease-modifying small-molecule drug candidate under investigation for the treatment of dry AMD. INM-089 is an intravitreal ("IVT") injectable formulation, which has been successfully delivered to the targeted area of the eye in preclinical studies at doses up to 10 times the calculated safety margin relative to the intended therapeutic dose. The Company continues to advance preclinical studies demonstrating significant functional and pathological improvements in a dry AMD disease study model. Next development steps: Preparing for a pre-IND meeting with the FDA GLP-enabling studies to support an IND submission Financial Commentary: BayMedica's commercial business generated revenues of $0.8 million for the three months ending December 31, 2025, compared to $1.1 million for the same period last year, reflecting a 26% decrease. This decrease is primarily attributed to drop in demand due to the currently pending changes in US legislation (Continuing Resolution and Appropriations Package (H.R. 5371, Section 781)) referenced below. The Company's research and development expenses were $0.6 million for the three months ending December 31, 2025, compared with $0.9 million for the three months ending December 31, 2024. The decrease in research and development expenses was primarily due to reduced spending on external contractors and research supplies, offset in part by an increase in compensation. We expect research and development expenses to increase substantially through the remainder of fiscal year 2026 as the Company advances preclinical work and IND-enabling studies for INM-901. The Company incurred general and administrative expenses of $1.6 million for the three months ended December 31, 2025, compared with $1.7 million for the three months ending December 31, 2024. As of December 31, 2025, the Company's cash, cash equivalents and short-term investments were $7.0 million, which compares to $11.1 million on June 30, 2025. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates. Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure into the fourth quarter of calendar year 2026, depending on the level and timing of BayMedica commercial revenues. As previously reported, U.S. congressional legislation H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") was signed into law. The Act, in its current form and without further amendment, will have a material negative impact on BayMedica, a subsidiary of the Company. Specifically, certain aspects of BayMedica's commercial business and its inventory of rare, non-intoxicating cannabinoids would be prohibited under the Act if it comes into force on November 12, 2026. It is unknown to the Company whether the sections of the Act that would impact BayMedica will ultimately go into effect on November 12, 2026, or at all, or if those sections will be replaced, impacted or amended by subsequent acts of U.S. policymakers. BayMedica is evaluating alternative options, but has not set a timetable for the conclusion of its evaluation, nor has it made any definitive decisions related to any potential alternative options at this time. In the meantime, BayMedica is continuing to sell its inventory of rare, non-intoxicating cannabinoids. Without timely, meaningful changes to the Act, we would need to write-off any inventory that BayMedica is unable to sell prior to the Act becoming effective and take other actions, which could include divesting BayMedica's commercial business, if possible, pivoting to other manufacturing techniques, if commercially viable, or discontinuing BayMedica's commercial business, all of which would have a material adverse effect on our business, results of operations and financial condition. Table 1. Consolidated Balance Sheet Expressed in U.S. Dollars Table 2. Consolidated Statements of Operations Expressed in U.S. Dollars Table 3. Consolidated Statements of Cash Flows Expressed in U.S. Dollars About InMed: InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the Act, the impact of the Act on BayMedica, any potential modifications to the Act and/or the timing thereof and the alternative options available to BayMedica and the Company; the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; statements regarding InMed's belief that modulating neuroinflammation is the primary focus of INM-901, while also targeting several additional biological pathways associated with disease progression; statements about pharmacokinetic studies in large animal models for INM-901; the advancement of chemistry, manufacturing, and controls (CMC) activities, the planning of GLP-enabling studies, and the preparation of an IND submission the further development; potential efficacy, and marketability of INM-089 for dry age-related macular degeneration; Preparing for a pre-IND meeting with the FDA in the second half of calendar 2026 for INM-089; GLP-enabling studies to support an IND submission; expectations regarding the sufficiency of the Company's strengthened balance sheet to fund operations, advance pharmaceutical development programs, and achieve milestones into the fourth quarter of calendar year 2026; and, other business initiatives, strategies, and prospects of the Company. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended December 31, 2025 and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283590

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated November 3, 2025, were voted upon by the shareholders. A total of 993,491 common shares of the Company, representing approximately 35.43% of the Company's 2,804,186 issued and outstanding common shares, were represented in person or by proxy at the Meeting. Results of the vote for the election of the board of directors (the "Board") at the Meeting are set out as follows: In addition, shareholders voted to approve CBIZ CPAs P.C. as the Company's auditors for the following year. Shareholders also voted to approve the potential issuance of 20% or more of the Company's common shares issued and outstanding as of December 13, 2024, pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b) (the "SEPA"). InMed filed a report of voting results on SEDAR+ at www.sedarplus.ca on December 17, 2025. About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1 604 416 0999 E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release, and oral statements by the Company and its executive officers and directors, contain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information includes, but is not limited to, statements about H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act"), the impact of the Act on BayMedica Inc., any potential modifications to the Act and/or the timing thereof and the alternative options available to BayMedica and the Company, statements about developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, and statements about the potential issuance of common shares pursuant to the SEPA. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any other documents filed or furnished with the Securities and Exchange Commission available on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278446

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of fiscal year 2026, which ended September 30, 2025. The Company's full financial statements and related MD&A for the first quarter ended September 30, 2025, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov. Eric A. Adams, InMed Chief Executive Officer, commented, "Fiscal 2026 is shaping up to be another strong year for InMed as we advance our lead program INM-901 toward clinical readiness. INM-901 continues to demonstrate compelling data across multiple preclinical models, reinforcing its potential as a differentiated small-molecule therapy targeting Alzheimer's disease. With IND-enabling activities advancing, we are entering an important stage in translating INM-901's scientific promise into clinical evaluation." Mr. Adams continued, "On the corporate front, the addition of two new directors further strengthens our Board's breadth of expertise and supports our continued growth and strategic execution. Additionally, the Company closed the quarter with approximately $9.3 million in cash allowing us to execute on program milestones into the fourth quarter of calendar year 2026." Business Update - Pharmaceutical Development Programs INM-901: Targeting multiple biological pathways associated with Alzheimer's disease InMed's proprietary small-molecule drug candidate INM-901 continues to advance as a potential treatment for Alzheimer's disease through its multiple mechanisms of action targeting several biological pathways associated with disease progression. This quarter, management presented a scientific poster at the 2025 Alzheimer's Association International Conference (AAIC) entitled, "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study ". This study measured hippocampal RNA expression, inflammatory markers, immunohistochemistry and behavioral differences using a 7-month treatment duration in subjects with more advanced disease to validate and expand upon previous findings, which demonstrated improvements in cognitive function, anxiety-related behavior, and sensory responsiveness. Through the remainder of fiscal 2026, InMed plans to further develop its Alzheimer's program, advancing Chemistry, Manufacturing, and Controls ("CMC") activities and preparing for a pre-IND meeting with the Food and Drug Administration ("FDA") and GLP-enabling studies to support an IND submission. INM-089: Neuroprotection in the treatment of dry age-related macular degeneration ("AMD") INM-089 is a proprietary small-molecule drug candidate under investigation for the treatment of dry AMD. The Company continues to advance preclinical studies demonstrating significant functional and pathological improvements in a dry AMD disease study model. Financial Commentary: BayMedica commercial business generated revenues of $1.1 million for the three months ending September 30, 2025, compared to $1.3 million for the same period last year, reflecting an 11% decrease. This decrease is primarily attributed to pricing adjustments on BayMedica's products over the prior year. Cost of goods sold decreased by 7% for the three months ended September 30, 2025, as compared to the three months ended September 30, 2024. The decrease in cost of goods sold is primarily the result of the Company lowering its supply chain and manufacturing costs which has led to improved margins over time. The Company's research and development expenses were $0.6 million for the three months ending September 30, 2025, compared with $0.7 million for the three months ending September 30, 2024. The decrease in research and development expenses was primarily due to reduced spending on external contractors and compensation. We expect research and development expenses to increase substantially through the remainder of fiscal year 2026 as the Company advances preclinical work and IND-enabling studies on INM-901. The Company incurred general and administrative expenses of $1.5 million for the three months ended September 30, 2025 and 2024. We anticipate general and administrative expenses to remain relatively stable for the remainder of fiscal 2026. As of September 30, 2025, the Company's cash and cash equivalents were $9.3 million, which compares to $11.1 million on June 30, 2025. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates. Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure into the fourth quarter of calendar year 2026, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses. Table 1. Consolidated Balance Sheet Expressed in U.S. Dollars Table 2. Consolidated Statements of Operations Expressed in U.S. Dollars Table 3. Consolidated Statements of Cash Flows Expressed in U.S. Dollars About InMed: InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; data from its INM-901 program at the Alzheimer's Association International Conference (AAIC) 2025; statements regarding InMed's belief in the potential of INM-901 as a multi-mechanism small molecule drug candidate for Alzheimer's disease; fiscal 2026 is shaping up to be another strong year for InMed advancing INM-901 toward clinical readiness; entering an important stage in translating INM-901's scientific promise into clinical evaluation; the advancement of chemistry, manufacturing, and controls (CMC) activities, the planning of GLP-enabling studies, and the preparation of an IND submission; the further development, potential efficacy, and marketability of INM-089 for dry age-related macular degeneration; expectations regarding the sufficiency of the Company's strengthened balance sheet to fund operations, advance pharmaceutical development programs, and achieve milestones into the fourth quarter of calendar year 2026; and, other business initiatives, strategies, and prospects of the Company. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273506

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026 Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC ("BayMedica"). The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2025, are available at www.inmedpharma.com and at www.sedar.com. Eric A. Adams, InMed Chief Executive Officer, commented, "Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901's potential as a small-molecule drug candidate that addresses Alzheimer's disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer's pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification." Mr. Adams continued, "Looking ahead, we remain focused on advancing IND-enabling studies and generating additional data that underscore INM-901's differentiated approach. Notably, the emphasis on neuroinflammation and multi-pathway approaches appears well aligned with the themes emerging from the recent Alzheimer's Association International Conference ("AAIC"), where leading researchers highlighted the need to move beyond amyloid and tau pathologies alone. We believe this convergence further validates our strategy and positions InMed to contribute meaningfully to the next generation of Alzheimer's treatments." "Additionally, InMed has significantly strengthened its balance sheet, positioning the Company to advance its pharmaceutical development programs and deliver on key milestones into the fourth quarter of calendar year 2026." Business Update Pharmaceutical Development Programs INM-901: Targeting several biological pathways associated with Alzheimer's disease ("AD") InMed's proprietary small molecule drug candidate INM-901 continues to advance as a potential treatment for Alzheimer's disease through its multiple mechanisms of action that target several biological pathways associated with disease progression. Throughout fiscal 2025, the Company announced several key findings for INM-901: Neuroinflammation Reported statistically significant reductions in neuroinflammation in a long-term (7-month dosing) preclinical study, including decreases in multiple plasma and brain markers of inflammation recognized as contributors to AD progression. Presented ex vivo study results showing significant reductions in neuroinflammation, including key pro-inflammatory markers, independent of amyloid beta or tau pathology. Cognition & Behavioral Outcomes Demonstrated improvements in cognitive function, memory, and locomotor activity, with statistical significance achieved in certain behavioral assessments in a well-established 5xFAD AD mouse model, using a longer treatment duration and subjects with more advanced disease to validate and expand upon previous findings. These findings were presented at AAIC 2025, the world's leading forum for Alzheimer's disease and dementia research. Drug Delivery Confirmed INM-901 can be administered orally while achieving therapeutic brain levels comparable to intraperitoneal injection in a in vivo model, offering important advantages over routes of administration used by currently approved products. Scientific Advisory and Intellectual Property Strengthened the Company's scientific advisory board with the appointment of Dr. Barry Greenberg, Director of the Alzheimer's Disease Translational Center and Associate Professor of Neurology at Johns Hopkins University School of Medicine. Expanded the Company's intellectual property with the filing of an additional international patent application under the Patent Cooperation Treaty ("PCT"), covering pharmaceutical composition and method of use for INM-901 in the treatment of neurodegenerative diseases, including Alzheimer's disease. In fiscal 2026, InMed plans to develop its Alzheimer's program, advancing Chemistry, Manufacturing, and Controls ("CMC") activities and preparing for a pre-IND meeting and GLP-enabling studies to support an IND submission. INM-089: Neuroprotection in the treatment of dry age-related macular degeneration ("AMD") INM-089 is a proprietary small molecule drug candidate being studied in the treatment of dry AMD. The Company continues to advance preclinical studies demonstrating significant functional and pathological improvements in a dry AMD disease study model In addition, the Company announced the selection of an intravitreal ("IVT") formulation for INM-089, which has been successfully delivered to the targeted area of the eye in preclinical studies at doses up to 10 times the calculated safety margin relative to the intended therapeutic dose. BayMedica commercial subsidiary BayMedica, a leading supplier of non-intoxicating rare cannabinoids to the health and wellness sector, has experienced sustained revenue growth during the fiscal year 2025, reaching $4.9M, representing an 8% increase over the previous year. BayMedica continues to hold a strong competitive position in its commercial portfolio of non-intoxicating rare cannabinoids. Financial commentary: For the year ended June 30, 2025, the Company recorded a net loss of $8.2M, compared with a net loss of $7.7M for the previous year. Research and development expenses were $2.9M for year ended June 30, 2025, compared with $3.2M for the year ended June 30, 2024. However, the Company expects research and development expenses to increase significantly in future periods as it continues to advance its pharmaceutical pipeline. The Company incurred general and administrative expenses of $6.6M for the year ended June 30, 2025, compared to $5.8M in the previous year. The increase was primarily from a combination of changes including higher legal expenses, and consulting fees, offset by a decrease in office and administrative fees. The Company realized sales of $4.9M in our BayMedica segment for the year ended June 30, 2025, representing an increase of $0.34M, or 8%, as compared to the year ended June 30, 2024. As of June 30, 2025, we had cash, cash equivalents and short-term investments of $11.1M. The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026, depending on the level and timing of realizing BayMedica revenues as well as the level and timing of the Company's operating expenses. Table 1. Consolidated Balance Sheet Expressed in U.S. Dollars Table 2. Consolidated Statements of Operations Expressed in U.S. Dollars Table 3. Consolidated Statements of Cash Flows Expressed in U.S. Dollars About InMed InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three drug development programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: statements regarding InMed's belief in the potential of INM-901 as a multi-mechanism small molecule drug candidate for Alzheimer's disease; expectations relating to the reduction of neuroinflammation and improvements in cognition and behavior observed in preclinical studies; the ability of INM-901 to provide disease-modifying benefits independent of amyloid or tau pathologies; the advancement of chemistry, manufacturing, and controls (CMC) activities, the planning of GLP-enabling studies, and the preparation of an IND submission; the ability to achieve therapeutic brain levels through oral administration; expectations relating to intellectual property protection; the further development, potential efficacy, and marketability of INM-089 for dry age-related macular degeneration, including its neuroprotective properties and intravitreal (IVT) delivery profile; the further development and potential commercial uses of INM-755; optimism regarding alignment of the Company's strategy with emerging industry trends and findings presented at the Alzheimer's Association International Conference (AAIC); expectations regarding the sufficiency of the Company's strengthened balance sheet to fund operations, advance pharmaceutical development programs, and achieve milestones into the fourth quarter of calendar year 2026; and, other business initiatives, strategies, and prospects of the Company. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267483

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2025 which ended March 31, 2025. The Company's full financial statements and related MD&A for the third quarter ended March 31, 2025, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov. Eric A. Adams, InMed's Chief Executive Officer, commented, "We continue to advance INM-901 as a differentiated approach to treating Alzheimer's disease by targeting neuroinflammation beyond conventional amyloid beta and tau-targeting strategies, and we look forward to sharing additional data in the near term." Adams continued, "On the commercial side, BayMedica continues to deliver stable revenues quarter-over-quarter. While gross margins were impacted by increased pricing pressure, we remain focused on optimizing our product mix and improving operational efficiencies." Business Update - Pharmaceutical Development Programs INM-901: Targeting multiple biological pathways in Alzheimer's disease ('AD') INM-901 is a proprietary small molecule drug candidate currently under development for the treatment of Alzheimer's disease (AD), with multiple mechanisms of action. Positive data from long-term in vivo preclinical AD studies highlighted INM-901's ability to significantly reduce neuroinflammation - a key factor in the onset and progression of Alzheimer's disease. The Company is currently conducting further research examining INM-901's impact on neuroinflammation independent of amyloid beta plaques and tau protein tangles which are the primary targets of conventional therapies. Additionally, analyses from this long-term study are underway, including detailed molecular evaluations aimed at elucidating INM-901's mechanisms of action and its potential role in addressing the complex pathology of AD. INM-089: Targeting the treatment of dry Age-related Macular Degeneration ("AMD") INM-089 is a proprietary small molecule drug candidate offering a differentiated approach to the treatment of dry age-related macular degeneration (AMD). Preclinical studies of INM-089 demonstrated significant functional and pathological improvements in a dry AMD disease study model. Key characteristics of INM-089 include: ability to proactively protect the retinal ganglion cells from cellular toxicity; demonstrates promise in preserving retinal function in an in vivo AMD disease model; improved the thickness of the outer nuclear layer of the retina where the photoreceptors are located; deliverable via preferred IVT formulation; and is a preferential signaling agonist of cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). Financial commentary: For the three months ended March 31, 2025, the Company reported a net loss of $2.12 million, compared to a net loss of $1.72 million in the same period the previous year. The increase was largely driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs. Pharmaceutical research and development and patent expenses were $0.91 million for the three months ended March 31, 2025, compared with $0.65 million for the three months ended March 31, 2024. The increase was primarily due to an increase in external contractors relating to our INM-901 and INM-089 programs and patent fees, offset by a decrease in compensation expense. General and administrative expenses were $1.33 million for the three months ended March 31, 2025, compared to $3.75 million the same period the previous year. The decrease resulted primarily from a combination of changes including lower accounting fees, share-based payments fees, and shareholder communication fees. As of March 31, 2025, the Company's cash, cash equivalents and short-term investments were $4.68 million, which compares to $6.57 million at June 30, 2024. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates and expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the third quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses. The Company expects to seek additional funding through equity financings, debt financings and/or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. BayMedica's commercial business generated revenues of $1.26 million for the three months ended March 31, 2025, compared to $1.18 million for the same period last year, reflecting an 8% increase. The increase in sales resulted from expanded marketing efforts and increased demand for certain cannabinoid products. Despite steady revenue quarter-over-quarter, gross margin declined due to competitive pricing pressures and increased sales of lower margin products. While market demand increased, the need to remain price competitive impacted overall profitability for the period. Certain segments of our supply chain may be negatively impacted by changes to tariffs by the U.S. and other countries. We are actively analyzing the potential effects and exploring strategies to mitigate the impact of tariffs on profitability in future quarters. Table 1. CONDENSED CONSOLIDATED BALANCE SHEETS Expressed in U.S. Dollars Table 2. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED Expressed in U.S. Dollars Table 3. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED Expressed in U.S. Dollars About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1 604 416 0999 E: [email protected] Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed's Alzheimer's program; the efficacy of INM-089, INM-089's ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed's AMD program; optimizing BayMedica's product mix and improving operational efficiencies; expectations that the Company's cash will be sufficient to fund its planned operating expenses and capital expenditures requirements into the third quarter of calendar year 2025; expectations that the Company will seek additional funding. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251814